
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The American Journal of Managed Care
over 29 years ago
Consideration in Pharmaceutical Conversion: Focus on Antihistaminesover 29 years ago
Issues in the Measurement of Satisfaction with Treatmentover 29 years ago
HMOs and the Efficiency of Healthcare Deliveryover 29 years ago
Abdominal Aortic Aneurysmover 29 years ago
Reducing Malpractice Risk Through More Effective Communication





